| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Data Interpretation, Statistical | 9 | 2018 | 2693 | 1.190 |
Why?
|
| Clinical Trials as Topic | 19 | 2018 | 8045 | 0.820 |
Why?
|
| Breast Neoplasms | 40 | 2019 | 21162 | 0.790 |
Why?
|
| Rare Diseases | 2 | 2018 | 630 | 0.780 |
Why?
|
| AIDS-Related Opportunistic Infections | 15 | 2003 | 663 | 0.660 |
Why?
|
| Retinal Vein Occlusion | 6 | 1998 | 149 | 0.610 |
Why?
|
| Statistics, Nonparametric | 5 | 2016 | 2846 | 0.610 |
Why?
|
| Disease-Free Survival | 12 | 2016 | 6850 | 0.600 |
Why?
|
| Aromatase Inhibitors | 3 | 2016 | 519 | 0.550 |
Why?
|
| Neoplasms, Second Primary | 4 | 2019 | 1061 | 0.510 |
Why?
|
| Nitriles | 3 | 2016 | 981 | 0.500 |
Why?
|
| Proportional Hazards Models | 19 | 2016 | 12534 | 0.500 |
Why?
|
| Triazoles | 3 | 2016 | 902 | 0.500 |
Why?
|
| Pneumonia, Pneumocystis | 9 | 2000 | 241 | 0.490 |
Why?
|
| Acquired Immunodeficiency Syndrome | 16 | 2007 | 2205 | 0.490 |
Why?
|
| Laser Coagulation | 5 | 1998 | 335 | 0.490 |
Why?
|
| Survival Rate | 23 | 2019 | 12825 | 0.470 |
Why?
|
| Models, Statistical | 13 | 2018 | 5091 | 0.470 |
Why?
|
| Survival Analysis | 20 | 2018 | 10100 | 0.450 |
Why?
|
| Disease Progression | 14 | 2018 | 13640 | 0.420 |
Why?
|
| Research Design | 10 | 2022 | 6207 | 0.420 |
Why?
|
| Sample Size | 5 | 2022 | 844 | 0.410 |
Why?
|
| Bayes Theorem | 4 | 2019 | 2354 | 0.390 |
Why?
|
| Lymphedema | 2 | 2014 | 526 | 0.350 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2014 | 407 | 0.340 |
Why?
|
| Computer Security | 1 | 2011 | 261 | 0.330 |
Why?
|
| Antineoplastic Agents | 18 | 2016 | 13643 | 0.320 |
Why?
|
| Receptor, erbB-2 | 8 | 2019 | 2597 | 0.320 |
Why?
|
| Survivors | 3 | 2016 | 2379 | 0.310 |
Why?
|
| Biometry | 7 | 2015 | 571 | 0.310 |
Why?
|
| Neoplasms | 8 | 2019 | 22350 | 0.300 |
Why?
|
| Quinazolines | 4 | 2016 | 1367 | 0.290 |
Why?
|
| Treatment Failure | 7 | 2007 | 2659 | 0.290 |
Why?
|
| Quality of Life | 5 | 2018 | 13476 | 0.280 |
Why?
|
| Retinal Vein | 2 | 1998 | 46 | 0.280 |
Why?
|
| Computer Simulation | 14 | 2018 | 6259 | 0.270 |
Why?
|
| Xenobiotics | 1 | 2006 | 71 | 0.270 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2011 | 1196 | 0.250 |
Why?
|
| Likelihood Functions | 6 | 2007 | 993 | 0.240 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2019 | 3552 | 0.240 |
Why?
|
| Humans | 201 | 2022 | 766766 | 0.240 |
Why?
|
| Osteoporosis | 1 | 2014 | 1581 | 0.230 |
Why?
|
| Cytomegalovirus Infections | 7 | 2002 | 838 | 0.230 |
Why?
|
| Choroid | 2 | 1998 | 364 | 0.230 |
Why?
|
| Registries | 6 | 2018 | 8351 | 0.220 |
Why?
|
| Medical History Taking | 4 | 2019 | 779 | 0.220 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2019 | 9404 | 0.220 |
Why?
|
| Female | 142 | 2019 | 396520 | 0.210 |
Why?
|
| Treatment Outcome | 25 | 2018 | 65273 | 0.210 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 3 | 1999 | 82 | 0.210 |
Why?
|
| Receptors, Progesterone | 4 | 2019 | 1159 | 0.210 |
Why?
|
| Colonoscopy | 4 | 2016 | 1409 | 0.200 |
Why?
|
| Data Collection | 3 | 2014 | 3321 | 0.200 |
Why?
|
| Carboplatin | 5 | 2015 | 789 | 0.200 |
Why?
|
| Mental Health | 1 | 2016 | 3270 | 0.200 |
Why?
|
| CA-125 Antigen | 2 | 2017 | 282 | 0.200 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2006 | 857 | 0.190 |
Why?
|
| Middle Aged | 98 | 2019 | 223257 | 0.190 |
Why?
|
| Macular Edema | 3 | 1997 | 387 | 0.190 |
Why?
|
| Adult | 92 | 2019 | 223307 | 0.180 |
Why?
|
| Regression Analysis | 6 | 2008 | 6329 | 0.180 |
Why?
|
| Heart Diseases | 1 | 2014 | 2817 | 0.180 |
Why?
|
| Aged | 78 | 2018 | 171343 | 0.170 |
Why?
|
| Cytomegalovirus | 6 | 2002 | 754 | 0.170 |
Why?
|
| National Health Programs | 2 | 2013 | 444 | 0.170 |
Why?
|
| Longitudinal Studies | 7 | 2010 | 14762 | 0.170 |
Why?
|
| Ethics, Medical | 2 | 1997 | 785 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2019 | 10384 | 0.170 |
Why?
|
| Markov Chains | 4 | 2015 | 974 | 0.160 |
Why?
|
| Hodgkin Disease | 3 | 2008 | 1384 | 0.160 |
Why?
|
| Receptors, Estrogen | 4 | 2019 | 2251 | 0.160 |
Why?
|
| Internet | 1 | 2011 | 3113 | 0.160 |
Why?
|
| Control Groups | 1 | 2019 | 107 | 0.160 |
Why?
|
| Radiotherapy | 6 | 2014 | 1497 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 20 | 2015 | 11872 | 0.150 |
Why?
|
| Time Factors | 29 | 2018 | 40149 | 0.150 |
Why?
|
| Toilet Training | 1 | 2017 | 18 | 0.150 |
Why?
|
| Wounds and Injuries | 4 | 2015 | 2513 | 0.150 |
Why?
|
| Algorithms | 10 | 2017 | 14072 | 0.150 |
Why?
|
| Neoplasm Staging | 14 | 2019 | 11218 | 0.150 |
Why?
|
| Candidiasis | 2 | 1999 | 372 | 0.150 |
Why?
|
| Appointments and Schedules | 1 | 2002 | 442 | 0.150 |
Why?
|
| Enuresis | 1 | 2017 | 45 | 0.150 |
Why?
|
| Data Display | 1 | 2018 | 174 | 0.150 |
Why?
|
| Genetic Counseling | 2 | 2016 | 634 | 0.150 |
Why?
|
| Carcinoma, Small Cell | 6 | 2002 | 419 | 0.140 |
Why?
|
| Pentamidine | 4 | 2000 | 44 | 0.140 |
Why?
|
| Models, Biological | 7 | 2002 | 9461 | 0.140 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2002 | 934 | 0.140 |
Why?
|
| Treatment Refusal | 1 | 2000 | 433 | 0.140 |
Why?
|
| Statistics as Topic | 1 | 2003 | 2351 | 0.140 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2001 | 1097 | 0.140 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2014 | 492 | 0.130 |
Why?
|
| Ovarian Neoplasms | 6 | 2017 | 4904 | 0.130 |
Why?
|
| Genes, BRCA1 | 3 | 2007 | 753 | 0.130 |
Why?
|
| Moral Obligations | 1 | 1997 | 91 | 0.130 |
Why?
|
| Male | 100 | 2019 | 364142 | 0.130 |
Why?
|
| Zidovudine | 6 | 1999 | 625 | 0.130 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2016 | 878 | 0.130 |
Why?
|
| Research | 3 | 2015 | 1977 | 0.130 |
Why?
|
| Proteinuria | 2 | 2011 | 613 | 0.130 |
Why?
|
| Mycoses | 2 | 1996 | 389 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2011 | 9357 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 13 | 2014 | 18075 | 0.130 |
Why?
|
| Family Health | 3 | 2011 | 1254 | 0.130 |
Why?
|
| Endpoint Determination | 1 | 2018 | 592 | 0.130 |
Why?
|
| Early Detection of Cancer | 5 | 2017 | 3236 | 0.120 |
Why?
|
| Neoplasms, Experimental | 3 | 1991 | 1227 | 0.120 |
Why?
|
| Skull Base Neoplasms | 4 | 2001 | 280 | 0.120 |
Why?
|
| Anti-Infective Agents | 5 | 2002 | 987 | 0.120 |
Why?
|
| Amidines | 1 | 2015 | 28 | 0.120 |
Why?
|
| BRCA2 Protein | 4 | 2015 | 802 | 0.120 |
Why?
|
| Employee Performance Appraisal | 1 | 2015 | 86 | 0.120 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2015 | 59 | 0.120 |
Why?
|
| Follow-Up Studies | 26 | 2019 | 39309 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2015 | 3796 | 0.120 |
Why?
|
| Gene Fusion | 1 | 2017 | 356 | 0.120 |
Why?
|
| Aged, 80 and over | 28 | 2018 | 59550 | 0.120 |
Why?
|
| Diabetic Retinopathy | 3 | 2011 | 1300 | 0.120 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2012 | 594 | 0.120 |
Why?
|
| Prostate-Specific Antigen | 2 | 2011 | 2463 | 0.120 |
Why?
|
| Multivariate Analysis | 8 | 2013 | 12064 | 0.120 |
Why?
|
| Academic Medical Centers | 3 | 2015 | 2783 | 0.120 |
Why?
|
| Cisplatin | 6 | 2015 | 1655 | 0.120 |
Why?
|
| Colorectal Neoplasms | 5 | 2014 | 6962 | 0.120 |
Why?
|
| Patient Compliance | 3 | 2002 | 2694 | 0.110 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2012 | 949 | 0.110 |
Why?
|
| Benzylamines | 1 | 2015 | 251 | 0.110 |
Why?
|
| Fluorescein Angiography | 6 | 2000 | 1086 | 0.110 |
Why?
|
| Virus Shedding | 2 | 2007 | 110 | 0.110 |
Why?
|
| Developed Countries | 1 | 2016 | 452 | 0.110 |
Why?
|
| Genes, BRCA2 | 2 | 2007 | 591 | 0.110 |
Why?
|
| BRCA1 Protein | 4 | 2015 | 1155 | 0.110 |
Why?
|
| Gene Expression Profiling | 5 | 2015 | 9525 | 0.110 |
Why?
|
| Disclosure | 2 | 1997 | 755 | 0.110 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2015 | 513 | 0.110 |
Why?
|
| Risk Management | 1 | 1997 | 558 | 0.110 |
Why?
|
| Clotrimazole | 3 | 1999 | 76 | 0.110 |
Why?
|
| Personnel Management | 1 | 2013 | 54 | 0.110 |
Why?
|
| Paget Disease, Extramammary | 2 | 2003 | 50 | 0.100 |
Why?
|
| Dapsone | 3 | 1999 | 55 | 0.100 |
Why?
|
| Incidence | 10 | 2022 | 21525 | 0.100 |
Why?
|
| Lung Neoplasms | 17 | 2008 | 13485 | 0.100 |
Why?
|
| Nervous System | 1 | 2016 | 542 | 0.100 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 7609 | 0.100 |
Why?
|
| Health Services Accessibility | 4 | 2016 | 5514 | 0.100 |
Why?
|
| Fluconazole | 3 | 1999 | 154 | 0.100 |
Why?
|
| Chordoma | 4 | 2001 | 349 | 0.100 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2014 | 260 | 0.100 |
Why?
|
| Bone Density Conservation Agents | 1 | 2019 | 791 | 0.100 |
Why?
|
| Mastectomy | 3 | 2016 | 1861 | 0.100 |
Why?
|
| Receptors, Steroid | 2 | 2017 | 157 | 0.100 |
Why?
|
| Receptors, Interleukin | 1 | 2013 | 243 | 0.100 |
Why?
|
| Women's Health Services | 1 | 2012 | 87 | 0.100 |
Why?
|
| Malpractice | 1 | 1997 | 561 | 0.100 |
Why?
|
| Carcinoma, Bronchogenic | 3 | 1986 | 86 | 0.100 |
Why?
|
| Risk | 4 | 2019 | 9602 | 0.100 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2016 | 388 | 0.090 |
Why?
|
| Mutation | 7 | 2015 | 30213 | 0.090 |
Why?
|
| Health Planning | 1 | 2013 | 233 | 0.090 |
Why?
|
| Prevalence | 6 | 2018 | 15835 | 0.090 |
Why?
|
| Glioma | 6 | 2005 | 3498 | 0.090 |
Why?
|
| Risk Factors | 23 | 2017 | 74881 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2014 | 4049 | 0.090 |
Why?
|
| Biostatistics | 1 | 2013 | 162 | 0.090 |
Why?
|
| Albuminuria | 2 | 2007 | 659 | 0.090 |
Why?
|
| Fatigue | 1 | 2018 | 1555 | 0.090 |
Why?
|
| Carcinogens | 2 | 1991 | 452 | 0.090 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2011 | 105 | 0.090 |
Why?
|
| Amyotrophic Lateral Sclerosis | 3 | 2019 | 1481 | 0.090 |
Why?
|
| Macula Lutea | 1 | 1992 | 180 | 0.090 |
Why?
|
| Prospective Studies | 23 | 2022 | 54871 | 0.090 |
Why?
|
| Brain Neoplasms | 10 | 2005 | 9101 | 0.090 |
Why?
|
| Lymph Node Excision | 2 | 2014 | 1267 | 0.090 |
Why?
|
| Liver | 1 | 2006 | 7571 | 0.090 |
Why?
|
| Informed Consent | 2 | 1998 | 1010 | 0.090 |
Why?
|
| Bone Neoplasms | 2 | 2019 | 2561 | 0.090 |
Why?
|
| Indians, North American | 1 | 2014 | 354 | 0.090 |
Why?
|
| Transcription Factors | 3 | 2006 | 12150 | 0.090 |
Why?
|
| Fundus Oculi | 3 | 1998 | 560 | 0.080 |
Why?
|
| Mycobacterium avium Complex | 2 | 1999 | 66 | 0.080 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2012 | 1757 | 0.080 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2008 | 543 | 0.080 |
Why?
|
| Diphosphates | 1 | 1989 | 89 | 0.080 |
Why?
|
| Antifungal Agents | 3 | 1999 | 769 | 0.080 |
Why?
|
| Technetium | 1 | 1989 | 325 | 0.080 |
Why?
|
| Prognosis | 25 | 2015 | 29948 | 0.080 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1996 | 807 | 0.080 |
Why?
|
| Gastroenterology | 1 | 2016 | 593 | 0.080 |
Why?
|
| Procarbazine | 5 | 1996 | 172 | 0.080 |
Why?
|
| Hospitals, Special | 1 | 1989 | 89 | 0.080 |
Why?
|
| Radiotherapy, Conformal | 3 | 2001 | 545 | 0.080 |
Why?
|
| Hemangioma, Cavernous | 1 | 1989 | 106 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 1 | 5 | 2007 | 3446 | 0.080 |
Why?
|
| Risk Assessment | 10 | 2012 | 24295 | 0.080 |
Why?
|
| Observation | 1 | 2010 | 310 | 0.080 |
Why?
|
| Monte Carlo Method | 5 | 2015 | 1250 | 0.080 |
Why?
|
| Tissue Plasminogen Activator | 5 | 1997 | 1164 | 0.080 |
Why?
|
| Porphyrins | 1 | 2010 | 352 | 0.080 |
Why?
|
| Medical Errors | 1 | 1997 | 1260 | 0.080 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 1512 | 0.080 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2012 | 523 | 0.070 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 2902 | 0.070 |
Why?
|
| Antiviral Agents | 4 | 2007 | 3070 | 0.070 |
Why?
|
| Human papillomavirus 16 | 1 | 2010 | 268 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 6 | 2003 | 2586 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2008 | 310 | 0.070 |
Why?
|
| Predictive Value of Tests | 10 | 2013 | 15416 | 0.070 |
Why?
|
| Didanosine | 2 | 1999 | 151 | 0.070 |
Why?
|
| Penetrance | 2 | 2008 | 388 | 0.070 |
Why?
|
| Methotrexate | 7 | 2005 | 1719 | 0.070 |
Why?
|
| Pneumocystis Infections | 1 | 2007 | 10 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 3 | 2012 | 5444 | 0.070 |
Why?
|
| Prostatic Neoplasms | 3 | 2011 | 11094 | 0.070 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2009 | 195 | 0.070 |
Why?
|
| Photons | 3 | 2000 | 588 | 0.070 |
Why?
|
| Sputum | 2 | 1999 | 514 | 0.070 |
Why?
|
| Faculty, Medical | 1 | 2015 | 1226 | 0.070 |
Why?
|
| Carcinoma, Papillary | 1 | 2012 | 791 | 0.070 |
Why?
|
| Hospitalization | 4 | 2022 | 10823 | 0.070 |
Why?
|
| Pneumocystis carinii | 1 | 2007 | 71 | 0.070 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2007 | 185 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2009 | 4522 | 0.070 |
Why?
|
| Genetic Testing | 4 | 2016 | 3591 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1989 | 718 | 0.070 |
Why?
|
| Mass Screening | 5 | 2014 | 5454 | 0.070 |
Why?
|
| Cyclophosphamide | 10 | 2005 | 2234 | 0.070 |
Why?
|
| Cancer Care Facilities | 1 | 1989 | 428 | 0.070 |
Why?
|
| Mucins | 1 | 2009 | 569 | 0.070 |
Why?
|
| CA-19-9 Antigen | 1 | 2006 | 109 | 0.070 |
Why?
|
| Bulimia | 2 | 2000 | 405 | 0.070 |
Why?
|
| United States | 15 | 2019 | 72951 | 0.060 |
Why?
|
| User-Computer Interface | 2 | 2011 | 1409 | 0.060 |
Why?
|
| Nursing Staff, Hospital | 1 | 1989 | 350 | 0.060 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2017 | 904 | 0.060 |
Why?
|
| Phenobarbital | 1 | 2006 | 192 | 0.060 |
Why?
|
| Cytochrome P-450 CYP2B1 | 1 | 2005 | 22 | 0.060 |
Why?
|
| Laryngeal Neoplasms | 1 | 1989 | 514 | 0.060 |
Why?
|
| Salvage Therapy | 4 | 2009 | 1274 | 0.060 |
Why?
|
| Carboxylesterase | 1 | 2005 | 31 | 0.060 |
Why?
|
| Primaquine | 2 | 1996 | 28 | 0.060 |
Why?
|
| Parathyroid Neoplasms | 1 | 2007 | 244 | 0.060 |
Why?
|
| Health Services Research | 1 | 2013 | 1811 | 0.060 |
Why?
|
| Thymoma | 2 | 2000 | 186 | 0.060 |
Why?
|
| Job Satisfaction | 1 | 1989 | 548 | 0.060 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2006 | 246 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2005 | 3609 | 0.060 |
Why?
|
| Germ-Line Mutation | 3 | 2000 | 1885 | 0.060 |
Why?
|
| Medical Staff, Hospital | 1 | 1989 | 602 | 0.060 |
Why?
|
| Insurance, Health | 2 | 2016 | 2520 | 0.060 |
Why?
|
| Cyclin-Dependent Kinases | 2 | 2000 | 661 | 0.060 |
Why?
|
| Parathyroidectomy | 1 | 2007 | 244 | 0.060 |
Why?
|
| Epidermal Growth Factor | 1 | 2008 | 697 | 0.060 |
Why?
|
| Personal Satisfaction | 1 | 1989 | 642 | 0.060 |
Why?
|
| Clindamycin | 2 | 1996 | 138 | 0.060 |
Why?
|
| Immunocompetence | 1 | 2005 | 138 | 0.060 |
Why?
|
| Models, Genetic | 3 | 2015 | 3450 | 0.060 |
Why?
|
| Radiation Injuries | 4 | 2000 | 1194 | 0.060 |
Why?
|
| Loss of Heterozygosity | 2 | 2015 | 663 | 0.060 |
Why?
|
| Cross-Over Studies | 1 | 2011 | 2108 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2015 | 2881 | 0.060 |
Why?
|
| Thymus Neoplasms | 2 | 2000 | 272 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2015 | 3721 | 0.060 |
Why?
|
| Developing Countries | 1 | 2016 | 2913 | 0.060 |
Why?
|
| ras Proteins | 1 | 2009 | 1055 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2019 | 638 | 0.060 |
Why?
|
| Homeodomain Proteins | 1 | 2013 | 2430 | 0.060 |
Why?
|
| Serotonin | 2 | 2000 | 1045 | 0.060 |
Why?
|
| Ischemia | 1 | 1992 | 1905 | 0.050 |
Why?
|
| Health Promotion | 2 | 2016 | 2209 | 0.050 |
Why?
|
| Parents | 1 | 2017 | 3593 | 0.050 |
Why?
|
| HIV Infections | 9 | 2000 | 17536 | 0.050 |
Why?
|
| Cell Line, Tumor | 7 | 2017 | 17088 | 0.050 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2005 | 646 | 0.050 |
Why?
|
| Pain | 1 | 2018 | 5098 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 1405 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 3 | 2000 | 1733 | 0.050 |
Why?
|
| Genetic Services | 1 | 2003 | 13 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2017 | 8621 | 0.050 |
Why?
|
| Neoplasm Metastasis | 8 | 2014 | 4891 | 0.050 |
Why?
|
| Vincristine | 5 | 2002 | 1039 | 0.050 |
Why?
|
| Doxorubicin | 9 | 2002 | 2229 | 0.050 |
Why?
|
| Teniposide | 1 | 2002 | 11 | 0.050 |
Why?
|
| HLA-DQ Antigens | 2 | 2000 | 190 | 0.050 |
Why?
|
| Personal Autonomy | 2 | 1998 | 316 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2017 | 5690 | 0.050 |
Why?
|
| Age Factors | 7 | 2014 | 18397 | 0.050 |
Why?
|
| Interviews as Topic | 5 | 2014 | 2741 | 0.050 |
Why?
|
| Brain Stem | 2 | 1999 | 858 | 0.050 |
Why?
|
| Adenocarcinoma | 4 | 2006 | 6359 | 0.050 |
Why?
|
| HIV-1 | 3 | 2000 | 6948 | 0.050 |
Why?
|
| Adolescent | 20 | 2013 | 88904 | 0.050 |
Why?
|
| Feces | 2 | 1999 | 1505 | 0.050 |
Why?
|
| Tachycardia | 3 | 1991 | 598 | 0.050 |
Why?
|
| Genetic Linkage | 1 | 2008 | 2342 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2016 | 2510 | 0.050 |
Why?
|
| Fenfluramine | 2 | 2000 | 58 | 0.050 |
Why?
|
| Leukocytes | 1 | 2010 | 2035 | 0.050 |
Why?
|
| Confidence Intervals | 3 | 2003 | 2921 | 0.050 |
Why?
|
| Jews | 3 | 2006 | 359 | 0.050 |
Why?
|
| Mathematics | 1 | 2003 | 696 | 0.050 |
Why?
|
| Diagnosis, Computer-Assisted | 3 | 2006 | 698 | 0.050 |
Why?
|
| Insurance Coverage | 1 | 2013 | 1945 | 0.050 |
Why?
|
| Ifosfamide | 1 | 2002 | 233 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2014 | 16044 | 0.050 |
Why?
|
| Cohort Studies | 5 | 2019 | 41710 | 0.050 |
Why?
|
| Aerosols | 3 | 2000 | 634 | 0.050 |
Why?
|
| HLA-DR Antigens | 2 | 2000 | 609 | 0.050 |
Why?
|
| Reproducibility of Results | 5 | 2014 | 20144 | 0.050 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2002 | 185 | 0.050 |
Why?
|
| Pancreatectomy | 1 | 2006 | 825 | 0.050 |
Why?
|
| Gene Expression | 3 | 2010 | 7585 | 0.050 |
Why?
|
| Melanoma | 4 | 2002 | 5700 | 0.050 |
Why?
|
| Paclitaxel | 5 | 2005 | 1727 | 0.050 |
Why?
|
| Estrogens | 1 | 2008 | 1528 | 0.050 |
Why?
|
| Quality of Health Care | 2 | 2012 | 4306 | 0.050 |
Why?
|
| Mitomycins | 4 | 1989 | 45 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2011 | 2234 | 0.050 |
Why?
|
| Drug Evaluation | 7 | 1992 | 642 | 0.050 |
Why?
|
| Retrospective Studies | 22 | 2013 | 81635 | 0.050 |
Why?
|
| Heterozygote | 4 | 2015 | 2795 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 4056 | 0.050 |
Why?
|
| Mexico | 2 | 2014 | 770 | 0.050 |
Why?
|
| Blood Donors | 2 | 1994 | 344 | 0.050 |
Why?
|
| Truth Disclosure | 2 | 1997 | 433 | 0.050 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2001 | 83 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2010 | 11920 | 0.040 |
Why?
|
| Prolactin | 2 | 2000 | 627 | 0.040 |
Why?
|
| Carcinogenicity Tests | 2 | 1991 | 39 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1985 | 1331 | 0.040 |
Why?
|
| Thymosin | 1 | 2000 | 47 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 1514 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 2 | 2015 | 9244 | 0.040 |
Why?
|
| Genotype | 6 | 2014 | 13036 | 0.040 |
Why?
|
| Erythrocytes | 1 | 1989 | 2412 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2016 | 4858 | 0.040 |
Why?
|
| Formamides | 2 | 1990 | 22 | 0.040 |
Why?
|
| Macrophages | 1 | 2015 | 5783 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2017 | 7868 | 0.040 |
Why?
|
| Cytological Techniques | 1 | 2001 | 217 | 0.040 |
Why?
|
| Pneumocystis | 1 | 1999 | 55 | 0.040 |
Why?
|
| Herpesvirus 1, Human | 1 | 2005 | 743 | 0.040 |
Why?
|
| Thymidine Kinase | 1 | 2000 | 286 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2000 | 705 | 0.040 |
Why?
|
| Naphthoquinones | 1 | 1999 | 60 | 0.040 |
Why?
|
| Ganciclovir | 1 | 2000 | 256 | 0.040 |
Why?
|
| Logistic Models | 4 | 2013 | 13278 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2009 | 2056 | 0.040 |
Why?
|
| Probability | 2 | 2005 | 2476 | 0.040 |
Why?
|
| Spiro Compounds | 2 | 1990 | 69 | 0.040 |
Why?
|
| Ophthalmoscopy | 2 | 2000 | 172 | 0.040 |
Why?
|
| Vinblastine | 4 | 1989 | 482 | 0.040 |
Why?
|
| Pigment Epithelium of Eye | 1 | 2000 | 209 | 0.040 |
Why?
|
| Polymorphism, Genetic | 2 | 2008 | 4249 | 0.040 |
Why?
|
| Chondrosarcoma | 2 | 2001 | 305 | 0.040 |
Why?
|
| Massachusetts | 6 | 2008 | 8891 | 0.040 |
Why?
|
| Radiotherapy Dosage | 6 | 2005 | 2911 | 0.040 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2000 | 151 | 0.040 |
Why?
|
| Fovea Centralis | 1 | 2000 | 126 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2008 | 5387 | 0.040 |
Why?
|
| Analysis of Variance | 7 | 2003 | 6214 | 0.040 |
Why?
|
| Recurrence | 7 | 1999 | 8507 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 1999 | 633 | 0.040 |
Why?
|
| Child | 14 | 2017 | 80668 | 0.040 |
Why?
|
| Brazil | 2 | 2013 | 1249 | 0.040 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2002 | 614 | 0.040 |
Why?
|
| Recombinant Proteins | 7 | 1997 | 6507 | 0.040 |
Why?
|
| Skin Neoplasms | 4 | 2008 | 5861 | 0.040 |
Why?
|
| China | 2 | 2014 | 2383 | 0.040 |
Why?
|
| Mitomycin | 3 | 1988 | 261 | 0.040 |
Why?
|
| Drug Therapy, Combination | 6 | 1999 | 6307 | 0.040 |
Why?
|
| Lymphoma, B-Cell | 1 | 2005 | 945 | 0.040 |
Why?
|
| Pituitary Gland | 1 | 2001 | 635 | 0.040 |
Why?
|
| Breast | 2 | 2011 | 1971 | 0.040 |
Why?
|
| Meningeal Neoplasms | 2 | 2000 | 1255 | 0.040 |
Why?
|
| Paternalism | 1 | 1998 | 49 | 0.040 |
Why?
|
| Remission, Spontaneous | 2 | 2003 | 384 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2007 | 2253 | 0.040 |
Why?
|
| Sensitivity and Specificity | 4 | 2015 | 14652 | 0.040 |
Why?
|
| Burns | 1 | 2009 | 1902 | 0.040 |
Why?
|
| Young Adult | 7 | 2015 | 59939 | 0.040 |
Why?
|
| Visual Acuity | 3 | 2000 | 2714 | 0.040 |
Why?
|
| Etoposide | 5 | 1995 | 638 | 0.040 |
Why?
|
| Carcinoid Tumor | 1 | 1999 | 225 | 0.040 |
Why?
|
| Random Allocation | 10 | 1992 | 2394 | 0.040 |
Why?
|
| Multiple Organ Failure | 2 | 2010 | 389 | 0.040 |
Why?
|
| Combined Modality Therapy | 7 | 2010 | 8540 | 0.040 |
Why?
|
| Drug Administration Schedule | 5 | 2015 | 4853 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 3 | 2015 | 2631 | 0.040 |
Why?
|
| Hypoglycemia | 2 | 1995 | 896 | 0.040 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2017 | 203 | 0.040 |
Why?
|
| Genes, MHC Class II | 1 | 1998 | 433 | 0.040 |
Why?
|
| Whistleblowing | 1 | 1997 | 7 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2017 | 205 | 0.040 |
Why?
|
| Radionuclide Imaging | 4 | 2007 | 1986 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2008 | 1960 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2007 | 2704 | 0.030 |
Why?
|
| Double-Blind Method | 4 | 2019 | 12430 | 0.030 |
Why?
|
| Oligodendroglioma | 1 | 1998 | 274 | 0.030 |
Why?
|
| Wireless Technology | 1 | 2017 | 99 | 0.030 |
Why?
|
| Socioeconomic Factors | 4 | 2014 | 7841 | 0.030 |
Why?
|
| Lomustine | 1 | 1996 | 60 | 0.030 |
Why?
|
| Neoplasm Proteins | 3 | 2002 | 3601 | 0.030 |
Why?
|
| Social Values | 1 | 1998 | 224 | 0.030 |
Why?
|
| Bone Diseases | 1 | 2000 | 412 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2002 | 1071 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2006 | 2392 | 0.030 |
Why?
|
| Multiple Myeloma | 1 | 2014 | 5194 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2002 | 723 | 0.030 |
Why?
|
| Compensation and Redress | 1 | 1997 | 66 | 0.030 |
Why?
|
| Alleles | 2 | 2014 | 6895 | 0.030 |
Why?
|
| Radiation Tolerance | 1 | 1999 | 476 | 0.030 |
Why?
|
| Protons | 2 | 2000 | 1097 | 0.030 |
Why?
|
| Maryland | 1 | 1997 | 277 | 0.030 |
Why?
|
| Taxoids | 1 | 2000 | 665 | 0.030 |
Why?
|
| Adenoma | 1 | 2007 | 2155 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 2008 | 2534 | 0.030 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 1996 | 72 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 3411 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2001 | 1615 | 0.030 |
Why?
|
| Bacterial Infections | 2 | 2002 | 1390 | 0.030 |
Why?
|
| Hyperglycemia | 2 | 1995 | 1389 | 0.030 |
Why?
|
| Cardiac Pacing, Artificial | 5 | 1993 | 881 | 0.030 |
Why?
|
| Age of Onset | 5 | 2007 | 3342 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2011 | 8066 | 0.030 |
Why?
|
| Organometallic Compounds | 2 | 1990 | 647 | 0.030 |
Why?
|
| Hypothalamus | 1 | 2001 | 1003 | 0.030 |
Why?
|
| Viruses | 1 | 1999 | 371 | 0.030 |
Why?
|
| Genome, Human | 1 | 2008 | 4443 | 0.030 |
Why?
|
| Hormones | 2 | 2000 | 866 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2017 | 385 | 0.030 |
Why?
|
| Animals | 14 | 2017 | 168930 | 0.030 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2008 | 2326 | 0.030 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2017 | 296 | 0.030 |
Why?
|
| Proteins | 3 | 2006 | 6002 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2010 | 10445 | 0.030 |
Why?
|
| Myocardial Infarction | 8 | 1990 | 11513 | 0.030 |
Why?
|
| Smad2 Protein | 1 | 2015 | 144 | 0.030 |
Why?
|
| Benzoquinones | 2 | 1985 | 198 | 0.030 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 1999 | 329 | 0.030 |
Why?
|
| Blood Glucose | 3 | 2007 | 6422 | 0.030 |
Why?
|
| Smad3 Protein | 1 | 2015 | 165 | 0.030 |
Why?
|
| Genetic Vectors | 3 | 2000 | 3401 | 0.030 |
Why?
|
| South Dakota | 1 | 2014 | 32 | 0.030 |
Why?
|
| Progesterone | 3 | 1988 | 752 | 0.030 |
Why?
|
| Antiphospholipid Syndrome | 1 | 1996 | 166 | 0.030 |
Why?
|
| Simplexvirus | 1 | 1998 | 805 | 0.030 |
Why?
|
| Child, Hospitalized | 1 | 1996 | 181 | 0.030 |
Why?
|
| Macular Degeneration | 2 | 2000 | 1015 | 0.030 |
Why?
|
| Anti-Arrhythmia Agents | 4 | 1993 | 772 | 0.030 |
Why?
|
| Rupture | 1 | 1996 | 444 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 1998 | 992 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1997 | 891 | 0.030 |
Why?
|
| Growth Inhibitors | 1 | 1995 | 375 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 1999 | 962 | 0.030 |
Why?
|
| Remission Induction | 6 | 2000 | 2413 | 0.030 |
Why?
|
| Social Responsibility | 1 | 1997 | 382 | 0.030 |
Why?
|
| Cultural Diversity | 1 | 1998 | 370 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 1989 | 4527 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2001 | 877 | 0.030 |
Why?
|
| Amino Acids | 1 | 2000 | 1711 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 1 | 2017 | 581 | 0.030 |
Why?
|
| West Indies | 1 | 2013 | 32 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2001 | 1374 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 2 | 1993 | 1622 | 0.030 |
Why?
|
| Head | 1 | 1999 | 926 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2006 | 12791 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 2 | 2005 | 2929 | 0.030 |
Why?
|
| Eye | 1 | 1997 | 710 | 0.030 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2013 | 82 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 1998 | 1206 | 0.030 |
Why?
|
| Anonymous Testing | 1 | 1992 | 10 | 0.030 |
Why?
|
| Consent Forms | 1 | 1993 | 55 | 0.030 |
Why?
|
| Nogalamycin | 1 | 1992 | 2 | 0.030 |
Why?
|
| Child, Preschool | 7 | 2017 | 42577 | 0.030 |
Why?
|
| Sarcoma, Kaposi | 1 | 1996 | 376 | 0.030 |
Why?
|
| Isoxazoles | 1 | 1994 | 233 | 0.030 |
Why?
|
| AIDS Serodiagnosis | 1 | 1994 | 220 | 0.030 |
Why?
|
| Authorship | 1 | 2015 | 289 | 0.020 |
Why?
|
| Polyarteritis Nodosa | 1 | 1973 | 70 | 0.020 |
Why?
|
| Pyridones | 1 | 2017 | 818 | 0.020 |
Why?
|
| Lymphokines | 1 | 1995 | 924 | 0.020 |
Why?
|
| Faculty | 1 | 2015 | 383 | 0.020 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2015 | 496 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 1998 | 1776 | 0.020 |
Why?
|
| Astrocytoma | 1 | 1996 | 773 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1996 | 1057 | 0.020 |
Why?
|
| Public Sector | 1 | 2013 | 265 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2010 | 5887 | 0.020 |
Why?
|
| Women | 1 | 1993 | 225 | 0.020 |
Why?
|
| Trust | 1 | 1997 | 532 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2008 | 4353 | 0.020 |
Why?
|
| Meningioma | 1 | 2000 | 1221 | 0.020 |
Why?
|
| Patient Participation | 2 | 1993 | 1445 | 0.020 |
Why?
|
| Blood Banks | 1 | 1992 | 108 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 1996 | 910 | 0.020 |
Why?
|
| Coronary Disease | 5 | 1989 | 5915 | 0.020 |
Why?
|
| Cluster Analysis | 2 | 2015 | 2717 | 0.020 |
Why?
|
| Latin America | 1 | 2013 | 416 | 0.020 |
Why?
|
| Thallium Radioisotopes | 2 | 1988 | 138 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1999 | 957 | 0.020 |
Why?
|
| Pilot Projects | 3 | 2017 | 8728 | 0.020 |
Why?
|
| Peripheral Nerves | 1 | 1995 | 490 | 0.020 |
Why?
|
| Mastectomy, Segmental | 1 | 2016 | 974 | 0.020 |
Why?
|
| Meningitis | 1 | 1993 | 219 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2017 | 3616 | 0.020 |
Why?
|
| Hallucinations | 1 | 1994 | 373 | 0.020 |
Why?
|
| Mammography | 2 | 2012 | 2429 | 0.020 |
Why?
|
| Fibronectins | 2 | 2010 | 722 | 0.020 |
Why?
|
| Morbidity | 2 | 2011 | 1754 | 0.020 |
Why?
|
| Aprotinin | 1 | 1991 | 94 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2001 | 11061 | 0.020 |
Why?
|
| Inflammation | 2 | 2010 | 10860 | 0.020 |
Why?
|
| Heart Arrest | 2 | 1993 | 1516 | 0.020 |
Why?
|
| Parenting | 1 | 1997 | 708 | 0.020 |
Why?
|
| Genomic Instability | 1 | 2015 | 716 | 0.020 |
Why?
|
| Organoplatinum Compounds | 2 | 1989 | 406 | 0.020 |
Why?
|
| Family | 2 | 2014 | 3209 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 1999 | 5753 | 0.020 |
Why?
|
| Private Sector | 1 | 2013 | 396 | 0.020 |
Why?
|
| Delayed Diagnosis | 1 | 2014 | 454 | 0.020 |
Why?
|
| Temporal Lobe | 1 | 1998 | 1716 | 0.020 |
Why?
|
| Arm | 1 | 2013 | 591 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2015 | 1168 | 0.020 |
Why?
|
| Feasibility Studies | 2 | 2017 | 5306 | 0.020 |
Why?
|
| Retinal Diseases | 1 | 1996 | 709 | 0.020 |
Why?
|
| Professional Role | 1 | 2013 | 314 | 0.020 |
Why?
|
| Gene Frequency | 2 | 2008 | 3624 | 0.020 |
Why?
|
| Exercise Test | 2 | 1988 | 2188 | 0.020 |
Why?
|
| Hospital Bed Capacity, under 100 | 1 | 1989 | 6 | 0.020 |
Why?
|
| Infusions, Intravenous | 4 | 2002 | 2228 | 0.020 |
Why?
|
| Cancer Vaccines | 1 | 1997 | 1042 | 0.020 |
Why?
|
| DNA Mutational Analysis | 3 | 2010 | 4114 | 0.020 |
Why?
|
| Professional Competence | 1 | 2013 | 429 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2006 | 22352 | 0.020 |
Why?
|
| Otosclerosis | 1 | 1991 | 113 | 0.020 |
Why?
|
| Drug Synergism | 2 | 2010 | 1756 | 0.020 |
Why?
|
| Health Care Costs | 2 | 2013 | 3242 | 0.020 |
Why?
|
| Laser Therapy | 1 | 1997 | 1108 | 0.020 |
Why?
|
| Brain Diseases | 1 | 1999 | 1552 | 0.020 |
Why?
|
| Vaccination | 1 | 2022 | 3434 | 0.020 |
Why?
|
| Models, Organizational | 1 | 2013 | 548 | 0.020 |
Why?
|
| Sotalol | 1 | 1989 | 47 | 0.020 |
Why?
|
| Nerve Regeneration | 1 | 1995 | 796 | 0.020 |
Why?
|
| Technetium Tc 99m Pyrophosphate | 1 | 1989 | 52 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2016 | 2425 | 0.020 |
Why?
|
| Germanium | 1 | 1989 | 7 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 3607 | 0.020 |
Why?
|
| Hearing Loss, Noise-Induced | 1 | 1991 | 144 | 0.020 |
Why?
|
| Idarubicin | 1 | 1989 | 59 | 0.020 |
Why?
|
| Personnel Turnover | 1 | 1989 | 89 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 2456 | 0.020 |
Why?
|
| Contraceptives, Oral | 1 | 2011 | 559 | 0.020 |
Why?
|
| Aziridines | 2 | 1985 | 23 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2013 | 1824 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 3 | 2008 | 6066 | 0.020 |
Why?
|
| Health Personnel | 1 | 2022 | 3384 | 0.020 |
Why?
|
| Diabetic Nephropathies | 2 | 2007 | 975 | 0.020 |
Why?
|
| Hemorrhage | 2 | 1991 | 3464 | 0.020 |
Why?
|
| Lod Score | 1 | 2008 | 600 | 0.020 |
Why?
|
| Sudden Infant Death | 1 | 1991 | 293 | 0.020 |
Why?
|
| Placebos | 3 | 2000 | 1659 | 0.020 |
Why?
|
| Teaching | 1 | 2015 | 1171 | 0.020 |
Why?
|
| Rats, Inbred F344 | 2 | 1999 | 820 | 0.020 |
Why?
|
| Postpartum Period | 1 | 2014 | 1195 | 0.020 |
Why?
|
| Sampling Studies | 1 | 1989 | 614 | 0.020 |
Why?
|
| Preventive Health Services | 1 | 2012 | 571 | 0.020 |
Why?
|
| Angina Pectoris | 2 | 1988 | 956 | 0.020 |
Why?
|
| Premenopause | 1 | 2011 | 1039 | 0.020 |
Why?
|
| Electrocardiography | 6 | 1991 | 6408 | 0.020 |
Why?
|
| Menarche | 1 | 2010 | 532 | 0.020 |
Why?
|
| Odds Ratio | 2 | 2010 | 9661 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 1996 | 0.020 |
Why?
|
| Affect | 1 | 1995 | 1494 | 0.020 |
Why?
|
| Referral and Consultation | 2 | 1997 | 3618 | 0.020 |
Why?
|
| Myelin Sheath | 1 | 1991 | 650 | 0.020 |
Why?
|
| Vision Disorders | 1 | 1994 | 1090 | 0.020 |
Why?
|
| Parity | 1 | 2010 | 931 | 0.020 |
Why?
|
| Case-Control Studies | 3 | 2013 | 22248 | 0.020 |
Why?
|
| Ventricular Fibrillation | 1 | 1989 | 538 | 0.020 |
Why?
|
| Physician-Patient Relations | 2 | 1997 | 3266 | 0.020 |
Why?
|
| Patient Selection | 2 | 2016 | 4252 | 0.020 |
Why?
|
| Retroviridae | 2 | 2000 | 846 | 0.020 |
Why?
|
| Sex Factors | 4 | 2008 | 10619 | 0.020 |
Why?
|
| Anti-HIV Agents | 2 | 1999 | 4562 | 0.020 |
Why?
|
| Mice | 4 | 2015 | 81889 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 2470 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 4570 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 1988 | 683 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2007 | 570 | 0.020 |
Why?
|
| Myocardium | 2 | 1990 | 4765 | 0.020 |
Why?
|
| Amifostine | 1 | 2005 | 39 | 0.020 |
Why?
|
| Cadherins | 1 | 2010 | 902 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 4142 | 0.020 |
Why?
|
| Hemophilia A | 2 | 1999 | 359 | 0.020 |
Why?
|
| Connecticut | 2 | 1996 | 365 | 0.020 |
Why?
|
| Crohn Disease | 1 | 1998 | 2286 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 1998 | 534 | 0.020 |
Why?
|
| Residence Characteristics | 2 | 2012 | 2116 | 0.020 |
Why?
|
| Biotransformation | 1 | 2005 | 165 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2010 | 10745 | 0.020 |
Why?
|
| Azirines | 1 | 1985 | 30 | 0.020 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2007 | 326 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 1998 | 640 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6512 | 0.020 |
Why?
|
| Death, Sudden, Cardiac | 1 | 1993 | 1567 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 1995 | 3227 | 0.020 |
Why?
|
| Electric Countershock | 1 | 1988 | 534 | 0.020 |
Why?
|
| Frameshift Mutation | 2 | 1997 | 392 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2000 | 562 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 1394 | 0.010 |
Why?
|
| Colon | 1 | 1973 | 1797 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2010 | 1969 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2007 | 957 | 0.010 |
Why?
|
| Phenotype | 2 | 2015 | 16724 | 0.010 |
Why?
|
| Body Weight | 3 | 1997 | 4626 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 1996 | 2254 | 0.010 |
Why?
|
| Goals | 1 | 1989 | 717 | 0.010 |
Why?
|
| Defibrillators, Implantable | 1 | 1993 | 1499 | 0.010 |
Why?
|
| Health Care Reform | 1 | 2013 | 1256 | 0.010 |
Why?
|
| New York | 2 | 1996 | 879 | 0.010 |
Why?
|
| Transplantation, Autologous | 2 | 1999 | 2127 | 0.010 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 2823 | 0.010 |
Why?
|
| Central Nervous System | 1 | 1991 | 1345 | 0.010 |
Why?
|
| Menopause | 1 | 2011 | 1657 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1996 | 4924 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 1646 | 0.010 |
Why?
|
| Prodrugs | 1 | 2005 | 274 | 0.010 |
Why?
|
| Severity of Illness Index | 3 | 2015 | 15908 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2010 | 2201 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 1986 | 855 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2005 | 895 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 4559 | 0.010 |
Why?
|
| Serum Albumin | 1 | 1986 | 675 | 0.010 |
Why?
|
| Hemostasis | 3 | 1991 | 467 | 0.010 |
Why?
|
| Occupational Diseases | 1 | 1991 | 1456 | 0.010 |
Why?
|
| Reward | 1 | 1989 | 980 | 0.010 |
Why?
|
| Pregnancy | 3 | 2014 | 30237 | 0.010 |
Why?
|
| Postmenopause | 1 | 2011 | 2517 | 0.010 |
Why?
|
| Sequence Deletion | 2 | 1997 | 1494 | 0.010 |
Why?
|
| DNA Primers | 2 | 1997 | 2826 | 0.010 |
Why?
|
| Aspirin | 2 | 1991 | 3135 | 0.010 |
Why?
|
| Survival | 1 | 2002 | 160 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2016 | 23619 | 0.010 |
Why?
|
| Electric Stimulation Therapy | 1 | 1988 | 635 | 0.010 |
Why?
|
| Thrombolytic Therapy | 1 | 1991 | 2053 | 0.010 |
Why?
|
| Health Status Disparities | 1 | 2013 | 1880 | 0.010 |
Why?
|
| Camptothecin | 1 | 2005 | 599 | 0.010 |
Why?
|
| Point Mutation | 2 | 1997 | 1591 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 1762 | 0.010 |
Why?
|
| Base Sequence | 3 | 1997 | 12415 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2012 | 3468 | 0.010 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2002 | 200 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 2 | 1999 | 6104 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 1998 | 7431 | 0.010 |
Why?
|
| Genetic Markers | 2 | 1998 | 2603 | 0.010 |
Why?
|
| Cell Survival | 1 | 2010 | 5748 | 0.010 |
Why?
|
| Medical Records | 2 | 1996 | 1408 | 0.010 |
Why?
|
| Government Programs | 1 | 2003 | 278 | 0.010 |
Why?
|
| Bleeding Time | 2 | 1991 | 83 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1993 | 4410 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 3804 | 0.010 |
Why?
|
| Leukopenia | 2 | 1995 | 213 | 0.010 |
Why?
|
| Vulvar Neoplasms | 1 | 2003 | 266 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2005 | 1787 | 0.010 |
Why?
|
| Lipofuscin | 1 | 2000 | 40 | 0.010 |
Why?
|
| Hyperprolactinemia | 1 | 2001 | 123 | 0.010 |
Why?
|
| Linear Models | 1 | 2010 | 5874 | 0.010 |
Why?
|
| Atovaquone | 1 | 1999 | 56 | 0.010 |
Why?
|
| Rats, Nude | 1 | 1999 | 105 | 0.010 |
Why?
|
| Coronary Angiography | 2 | 1988 | 4508 | 0.010 |
Why?
|
| Malignant Carcinoid Syndrome | 1 | 1999 | 31 | 0.010 |
Why?
|
| Primary Health Care | 1 | 1996 | 4735 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 2000 | 280 | 0.010 |
Why?
|
| Brain | 2 | 2005 | 27159 | 0.010 |
Why?
|
| Brain Abscess | 1 | 2000 | 122 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2009 | 2976 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2003 | 792 | 0.010 |
Why?
|
| Cross-Sectional Studies | 4 | 2007 | 26310 | 0.010 |
Why?
|
| HLA-DP Antigens | 1 | 1998 | 25 | 0.010 |
Why?
|
| Fibrinolytic Agents | 1 | 1988 | 2078 | 0.010 |
Why?
|
| Fractures, Spontaneous | 1 | 2000 | 230 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2011 | 36567 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1988 | 2258 | 0.010 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1999 | 228 | 0.010 |
Why?
|
| Spinal Cord Compression | 1 | 2000 | 234 | 0.010 |
Why?
|
| Neoplasm Transplantation | 2 | 1999 | 2012 | 0.010 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2000 | 203 | 0.010 |
Why?
|
| Ethics Committees | 1 | 1998 | 51 | 0.010 |
Why?
|
| Comorbidity | 2 | 2008 | 10580 | 0.010 |
Why?
|
| Papillomavirus Infections | 1 | 2010 | 1639 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 1998 | 275 | 0.010 |
Why?
|
| Tryptophan | 1 | 2000 | 484 | 0.010 |
Why?
|
| Cholesterol | 1 | 2007 | 2903 | 0.010 |
Why?
|
| Ethics Committees, Clinical | 1 | 1998 | 56 | 0.010 |
Why?
|
| Hematologic Diseases | 2 | 1996 | 502 | 0.010 |
Why?
|
| Quality Improvement | 1 | 2013 | 3850 | 0.010 |
Why?
|
| Stereotaxic Techniques | 1 | 2000 | 551 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 1998 | 350 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1997 | 305 | 0.010 |
Why?
|
| Virus Replication | 1 | 2005 | 2457 | 0.010 |
Why?
|
| Hypercalcemia | 1 | 2000 | 425 | 0.010 |
Why?
|
| Nausea | 1 | 2000 | 681 | 0.010 |
Why?
|
| Rats | 3 | 1999 | 23717 | 0.010 |
Why?
|
| Asthma | 1 | 1996 | 6268 | 0.010 |
Why?
|
| Cognition | 1 | 1995 | 7057 | 0.010 |
Why?
|
| Drug Eruptions | 1 | 2000 | 335 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 2000 | 899 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1998 | 418 | 0.010 |
Why?
|
| Leucine Zippers | 1 | 1997 | 116 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2010 | 4045 | 0.010 |
Why?
|
| Platelet Aggregation | 2 | 1991 | 769 | 0.010 |
Why?
|
| Pruritus | 1 | 2000 | 378 | 0.010 |
Why?
|
| Light Coagulation | 1 | 1996 | 72 | 0.010 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 1996 | 84 | 0.010 |
Why?
|
| Administration, Oral | 2 | 1995 | 4018 | 0.010 |
Why?
|
| Boston | 1 | 1989 | 9346 | 0.010 |
Why?
|
| Physicians | 1 | 2014 | 4591 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 1999 | 738 | 0.010 |
Why?
|
| Hypothyroidism | 1 | 2001 | 665 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2000 | 616 | 0.010 |
Why?
|
| Naphthacenes | 2 | 1985 | 7 | 0.010 |
Why?
|
| Retinal Hemorrhage | 1 | 1996 | 98 | 0.010 |
Why?
|
| Aclarubicin | 2 | 1985 | 12 | 0.010 |
Why?
|
| Retinal Artery | 1 | 1996 | 109 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1998 | 832 | 0.010 |
Why?
|
| SEER Program | 1 | 2001 | 1443 | 0.010 |
Why?
|
| Diphosphonates | 1 | 2000 | 625 | 0.010 |
Why?
|
| Pancreatic Hormones | 1 | 1995 | 12 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 1989 | 3927 | 0.010 |
Why?
|
| Smoking | 1 | 2012 | 9077 | 0.010 |
Why?
|
| Spouses | 1 | 1998 | 286 | 0.010 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 1995 | 81 | 0.010 |
Why?
|
| Deoxycytidine | 1 | 2000 | 886 | 0.010 |
Why?
|
| Infusions, Parenteral | 2 | 1985 | 395 | 0.010 |
Why?
|
| Infarction | 1 | 1996 | 247 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1999 | 1392 | 0.010 |
Why?
|
| Hypogonadism | 1 | 2001 | 802 | 0.010 |
Why?
|
| Diagnosis-Related Groups | 1 | 1996 | 445 | 0.010 |
Why?
|
| Neutropenia | 1 | 2000 | 894 | 0.010 |
Why?
|
| Glucose Clamp Technique | 1 | 1995 | 262 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2002 | 5022 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1999 | 1527 | 0.010 |
Why?
|
| Introns | 1 | 1997 | 966 | 0.010 |
Why?
|
| Vitreous Body | 1 | 1976 | 401 | 0.010 |
Why?
|
| Immunization | 1 | 1998 | 1218 | 0.010 |
Why?
|
| Pneumonectomy | 1 | 2001 | 1147 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1996 | 747 | 0.010 |
Why?
|
| AIDS-Related Complex | 1 | 1993 | 107 | 0.010 |
Why?
|
| Microcomputers | 1 | 1994 | 139 | 0.010 |
Why?
|
| Thiotepa | 1 | 1993 | 66 | 0.010 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 1997 | 475 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1996 | 17608 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 1997 | 1587 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1995 | 365 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1998 | 1741 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1995 | 591 | 0.010 |
Why?
|
| Red Cross | 1 | 1992 | 12 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2002 | 2021 | 0.010 |
Why?
|
| Menogaril | 1 | 1992 | 4 | 0.010 |
Why?
|
| Fever | 1 | 2000 | 1607 | 0.010 |
Why?
|
| Reference Values | 1 | 2000 | 4913 | 0.010 |
Why?
|
| Glucagon | 1 | 1995 | 534 | 0.010 |
Why?
|
| Scleroderma, Systemic | 1 | 1996 | 346 | 0.010 |
Why?
|
| Behavioral Research | 1 | 1992 | 52 | 0.010 |
Why?
|
| Growth Hormone | 1 | 1995 | 572 | 0.010 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1996 | 742 | 0.010 |
Why?
|
| Injections, Spinal | 1 | 1993 | 317 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2000 | 2605 | 0.010 |
Why?
|
| Norepinephrine | 1 | 1995 | 898 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2008 | 18984 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2001 | 1667 | 0.010 |
Why?
|
| Heart Ventricles | 3 | 1988 | 3832 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2000 | 1172 | 0.010 |
Why?
|
| Gender Identity | 1 | 1998 | 767 | 0.010 |
Why?
|
| Ambulatory Care | 2 | 1996 | 2779 | 0.010 |
Why?
|
| RNA Splicing | 1 | 1996 | 903 | 0.010 |
Why?
|
| Sciatic Nerve | 1 | 1995 | 627 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 1994 | 15831 | 0.010 |
Why?
|
| Epinephrine | 1 | 1995 | 782 | 0.010 |
Why?
|
| Personality Inventory | 1 | 1994 | 1019 | 0.010 |
Why?
|
| Research Subjects | 1 | 1993 | 248 | 0.010 |
Why?
|
| Metallurgy | 1 | 1991 | 90 | 0.010 |
Why?
|
| Exons | 1 | 1997 | 2392 | 0.010 |
Why?
|
| Forecasting | 1 | 2000 | 2936 | 0.010 |
Why?
|
| Dogs | 2 | 1991 | 3834 | 0.010 |
Why?
|
| Altretamine | 1 | 1990 | 11 | 0.010 |
Why?
|
| Mining | 1 | 1991 | 93 | 0.010 |
Why?
|
| Bone Conduction | 1 | 1991 | 102 | 0.010 |
Why?
|
| Cerebrospinal Fluid | 1 | 1993 | 540 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2002 | 3561 | 0.010 |
Why?
|
| Bone and Bones | 1 | 2000 | 2559 | 0.010 |
Why?
|
| Microsurgery | 1 | 1995 | 798 | 0.010 |
Why?
|
| Intelligence | 1 | 1995 | 925 | 0.010 |
Why?
|
| Fibrinolysis | 1 | 1991 | 331 | 0.010 |
Why?
|
| Transfection | 1 | 1997 | 5754 | 0.010 |
Why?
|
| Myocardial Revascularization | 1 | 1993 | 795 | 0.010 |
Why?
|
| Confidentiality | 1 | 1994 | 607 | 0.010 |
Why?
|
| Auditory Threshold | 1 | 1991 | 369 | 0.010 |
Why?
|
| Lung | 1 | 1987 | 10067 | 0.000 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1993 | 530 | 0.000 |
Why?
|
| Demography | 1 | 1993 | 1641 | 0.000 |
Why?
|
| Biopsy | 1 | 2000 | 6779 | 0.000 |
Why?
|
| Hematopoiesis | 1 | 1998 | 2060 | 0.000 |
Why?
|
| Nutritional Status | 1 | 1997 | 1621 | 0.000 |
Why?
|
| Eye Diseases | 1 | 1994 | 660 | 0.000 |
Why?
|
| Adenosine Diphosphate | 1 | 1989 | 421 | 0.000 |
Why?
|
| Pregnant Women | 1 | 1993 | 576 | 0.000 |
Why?
|
| Cell Cycle | 1 | 1996 | 2926 | 0.000 |
Why?
|
| Hematocrit | 1 | 1989 | 622 | 0.000 |
Why?
|
| Antibodies, Viral | 1 | 1999 | 3212 | 0.000 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 1989 | 426 | 0.000 |
Why?
|
| Axons | 1 | 1995 | 1675 | 0.000 |
Why?
|
| Infant | 3 | 1996 | 36461 | 0.000 |
Why?
|
| Immunity, Innate | 1 | 1999 | 3077 | 0.000 |
Why?
|
| Risk-Taking | 1 | 1992 | 1021 | 0.000 |
Why?
|
| Tumor Suppressor Proteins | 1 | 1997 | 2801 | 0.000 |
Why?
|
| Hydrocortisone | 1 | 1995 | 1838 | 0.000 |
Why?
|
| Psychomotor Performance | 1 | 1995 | 1885 | 0.000 |
Why?
|
| Vindesine | 1 | 1986 | 12 | 0.000 |
Why?
|
| Apoptosis | 1 | 2002 | 9513 | 0.000 |
Why?
|
| Anthraquinones | 1 | 1985 | 41 | 0.000 |
Why?
|
| Organ Size | 1 | 1991 | 2261 | 0.000 |
Why?
|
| Visual Perception | 1 | 1994 | 1392 | 0.000 |
Why?
|
| Acute Disease | 1 | 1996 | 7241 | 0.000 |
Why?
|
| Cell Cycle Proteins | 1 | 1997 | 3439 | 0.000 |
Why?
|
| Mitoxantrone | 1 | 1985 | 148 | 0.000 |
Why?
|
| Heart Conduction System | 1 | 1991 | 1007 | 0.000 |
Why?
|
| Coronary Thrombosis | 1 | 1988 | 440 | 0.000 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1993 | 1814 | 0.000 |
Why?
|
| Stroke Volume | 2 | 1989 | 5618 | 0.000 |
Why?
|
| Oxygen | 1 | 1996 | 4251 | 0.000 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1995 | 8106 | 0.000 |
Why?
|
| Women's Health | 1 | 1993 | 2081 | 0.000 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1994 | 6020 | 0.000 |
Why?
|
| Cell Line | 1 | 1997 | 15563 | 0.000 |
Why?
|
| Isoenzymes | 1 | 1988 | 1688 | 0.000 |
Why?
|
| Disease Models, Animal | 2 | 2000 | 18330 | 0.000 |
Why?
|
| Perfusion | 1 | 1988 | 1409 | 0.000 |
Why?
|
| Angiography | 1 | 1988 | 1595 | 0.000 |
Why?
|
| Emergencies | 1 | 1989 | 1223 | 0.000 |
Why?
|
| Myocardial Contraction | 1 | 1988 | 1516 | 0.000 |
Why?
|
| Birth Weight | 1 | 1991 | 2123 | 0.000 |
Why?
|
| Insulin | 1 | 1997 | 6608 | 0.000 |
Why?
|
| Neuropsychological Tests | 1 | 1995 | 7119 | 0.000 |
Why?
|
| Radiography | 1 | 1973 | 6968 | 0.000 |
Why?
|
| Depressive Disorder | 1 | 1994 | 3715 | 0.000 |
Why?
|
| Ventricular Function, Left | 1 | 1993 | 3935 | 0.000 |
Why?
|
| Muscle, Skeletal | 1 | 1995 | 4970 | 0.000 |
Why?
|
| DNA-Binding Proteins | 1 | 1997 | 9611 | 0.000 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 1991 | 2763 | 0.000 |
Why?
|
| Anaphylaxis | 1 | 1985 | 738 | 0.000 |
Why?
|
| Hemodynamics | 1 | 1988 | 4188 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2001 | 20708 | 0.000 |
Why?
|
| Coronary Vessels | 1 | 1988 | 3100 | 0.000 |
Why?
|
| Heart Rate | 1 | 1988 | 4207 | 0.000 |
Why?
|
| Heart | 1 | 1988 | 4425 | 0.000 |
Why?
|
| Heart Defects, Congenital | 1 | 1991 | 4712 | 0.000 |
Why?
|
| Ependymoma | 1 | 1976 | 326 | 0.000 |
Why?
|
| Rabbits | 1 | 1976 | 4752 | 0.000 |
Why?
|
| Retina | 1 | 1976 | 2660 | 0.000 |
Why?
|
| Carcinoma | 1 | 1976 | 2324 | 0.000 |
Why?
|